RNF213 Double Nickase Plasmid (h): sc-418450-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- RNF213 Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- RNF213 Double Nickase Plasmid (h) and RNF213 Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting RNF213. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: RNF213 Antibody (5C12): sc-293391
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
RNF213 Double Nickase Plasmid (h) | sc-418450-NIC | 20 µg | $410.00 | |||
RNF213 Double Nickase Plasmid (h2) | sc-418450-NIC-2 | 20 µg | $410.00 |
RNF213 encodes a large RING finger–containing E3 ubiquitin ligase and AAA+ ATPase that contributes to ubiquitin-dependent regulation of protein turnover and stress-responsive signaling. RNF213 has been implicated in pathways coordinating endothelial and vascular homeostasis, inflammatory signaling, and cellular responses to hypoxia and metabolic stress, consistent with roles in angiogenic remodeling. Genetic variation and altered RNF213 function are strongly associated with Moyamoya disease and other cerebrovascular and vasculopathic phenotypes, motivating mechanistic studies in relevant human cell models. In addition, RNF213 activity has been linked to modulation of innate immune pathways, making it a useful node for dissecting cross-talk between ubiquitination, inflammation, and vascular biology.
RNF213 Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the RNF213 locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within RNF213. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt RNF213 function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of RNF213-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.